Batoprotafib (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Batoprotafib" in English language version.

refsWebsite

Global rank English rank

4^th place

4^th place

2^nd place

2^nd place

18^th place

17^th place

doi.org (Global: 2^nd place; English: 2^nd place)

LaMarche MJ, Acker M, Argintaru A, Bauer D, Boisclair J, Chan H, et al. (November 2020). "Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer". Journal of Medicinal Chemistry. 63 (22): 13578–13594. doi:10.1021/acs.jmedchem.0c01170. PMID 32910655.
Wang J, Calizo A, Zhang L, Pino JC, Lyu Y, Pollard K, et al. (November 2023). "CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors". Science Advances. 9 (47) eadg8876. Bibcode:2023SciA....9G8876W. doi:10.1126/sciadv.adg8876. PMC 10672174. PMID 38000020.
Prahallad A, Weiss A, Voshol H, Kerr G, Sprouffske K, Yuan T, et al. (December 2023). "CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung Cancer". Cancer Research. 83 (24): 4130–4141. doi:10.1158/0008-5472.CAN-23-1127. PMC 10722132. PMID 37934115.
Valencia-Sama I, Kee L, Christopher G, Ohh M, Layeghifard M, Shlien A, et al. (December 2023). "SHP2 Inhibition with TNO155 Increases Efficacy and Overcomes Resistance of ALK Inhibitors in Neuroblastoma". Cancer Research Communications. 3 (12): 2608–2622. doi:10.1158/2767-9764.CRC-23-0234. PMC 10752212. PMID 38032104.
Chai AW, Tan YH, Ooi S, Yee PS, Yee SM, Cheong SC (November 2024). "TNO155 is a selective SHP2 inhibitor to target PTPN11-dependent oral squamous cell carcinoma". Heliyon. 10 (21) e39677. Bibcode:2024Heliy..1039677C. doi:10.1016/j.heliyon.2024.e39677. PMC 11550046. PMID 39524880.
Oya Y, Imaizumi K, Mitsudomi T (August 2024). "The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?". Lung Cancer. 194 107886. doi:10.1016/j.lungcan.2024.107886. PMID 39047616.

harvard.edu (Global: 18^th place; English: 17^th place)

ui.adsabs.harvard.edu

Wang J, Calizo A, Zhang L, Pino JC, Lyu Y, Pollard K, et al. (November 2023). "CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors". Science Advances. 9 (47) eadg8876. Bibcode:2023SciA....9G8876W. doi:10.1126/sciadv.adg8876. PMC 10672174. PMID 38000020.
Chai AW, Tan YH, Ooi S, Yee PS, Yee SM, Cheong SC (November 2024). "TNO155 is a selective SHP2 inhibitor to target PTPN11-dependent oral squamous cell carcinoma". Heliyon. 10 (21) e39677. Bibcode:2024Heliy..1039677C. doi:10.1016/j.heliyon.2024.e39677. PMC 11550046. PMID 39524880.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

LaMarche MJ, Acker M, Argintaru A, Bauer D, Boisclair J, Chan H, et al. (November 2020). "Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer". Journal of Medicinal Chemistry. 63 (22): 13578–13594. doi:10.1021/acs.jmedchem.0c01170. PMID 32910655.
Wang J, Calizo A, Zhang L, Pino JC, Lyu Y, Pollard K, et al. (November 2023). "CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors". Science Advances. 9 (47) eadg8876. Bibcode:2023SciA....9G8876W. doi:10.1126/sciadv.adg8876. PMC 10672174. PMID 38000020.
Prahallad A, Weiss A, Voshol H, Kerr G, Sprouffske K, Yuan T, et al. (December 2023). "CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung Cancer". Cancer Research. 83 (24): 4130–4141. doi:10.1158/0008-5472.CAN-23-1127. PMC 10722132. PMID 37934115.
Valencia-Sama I, Kee L, Christopher G, Ohh M, Layeghifard M, Shlien A, et al. (December 2023). "SHP2 Inhibition with TNO155 Increases Efficacy and Overcomes Resistance of ALK Inhibitors in Neuroblastoma". Cancer Research Communications. 3 (12): 2608–2622. doi:10.1158/2767-9764.CRC-23-0234. PMC 10752212. PMID 38032104.
Chai AW, Tan YH, Ooi S, Yee PS, Yee SM, Cheong SC (November 2024). "TNO155 is a selective SHP2 inhibitor to target PTPN11-dependent oral squamous cell carcinoma". Heliyon. 10 (21) e39677. Bibcode:2024Heliy..1039677C. doi:10.1016/j.heliyon.2024.e39677. PMC 11550046. PMID 39524880.
Oya Y, Imaizumi K, Mitsudomi T (August 2024). "The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?". Lung Cancer. 194 107886. doi:10.1016/j.lungcan.2024.107886. PMID 39047616.

ncbi.nlm.nih.gov

Wang J, Calizo A, Zhang L, Pino JC, Lyu Y, Pollard K, et al. (November 2023). "CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors". Science Advances. 9 (47) eadg8876. Bibcode:2023SciA....9G8876W. doi:10.1126/sciadv.adg8876. PMC 10672174. PMID 38000020.
Prahallad A, Weiss A, Voshol H, Kerr G, Sprouffske K, Yuan T, et al. (December 2023). "CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung Cancer". Cancer Research. 83 (24): 4130–4141. doi:10.1158/0008-5472.CAN-23-1127. PMC 10722132. PMID 37934115.
Valencia-Sama I, Kee L, Christopher G, Ohh M, Layeghifard M, Shlien A, et al. (December 2023). "SHP2 Inhibition with TNO155 Increases Efficacy and Overcomes Resistance of ALK Inhibitors in Neuroblastoma". Cancer Research Communications. 3 (12): 2608–2622. doi:10.1158/2767-9764.CRC-23-0234. PMC 10752212. PMID 38032104.
Chai AW, Tan YH, Ooi S, Yee PS, Yee SM, Cheong SC (November 2024). "TNO155 is a selective SHP2 inhibitor to target PTPN11-dependent oral squamous cell carcinoma". Heliyon. 10 (21) e39677. Bibcode:2024Heliy..1039677C. doi:10.1016/j.heliyon.2024.e39677. PMC 11550046. PMID 39524880.